April 5, 2011

Data from Two Mipomersen Phase 3 Trials Presented at ACC

- Study in Patients with Severe Familial Hypercholesterolemia Meets Primary Endpoint with 36 Percent LDL-C Reduction -

 

Data from Two Mipomersen Phase 3 Trials Presented at ACC
- Study in Patients with Severe Familial Hypercholesterolemia Meets Primary Endpoint with 36 Percent LDL-C Reduction -

Paris, France – Cambridge, Massachusetts, and Carlsbad, California – April 5, 2011 – Genzyme (NASDAQ: GENZ), a subsidiary of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) announced today that data from two phase 3 studies of mipomersen in patients who had high cholesterol levels while on lipid-lowering therapy were presented at the American College of Cardiology’s 60th Annual Scientific Session.